Hopamine as Personalized Medicine for Persons with Parkinson's Disease.
Dopamine
Parkinson’s disease
hopamine
hope
personalized care management
personalized medicine
Journal
Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362
Informations de publication
Date de publication:
2023
2023
Historique:
pubmed:
23
2
2023
medline:
22
3
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
Prescribing dopamine replacement therapy remains the most common approach used by physicians who strive to support persons with Parkinson's disease. In this viewpoint, we argue that instead of merely prescribing dopamine, healthcare professionals should particularly encourage and enable persons with Parkinson's disease to draft their own personalized prescription of "hopamine". The term hopamine is a self-invented neologism representing the uniquely personal set of hopes, desires, experiences, and skills of each individual with a dopamine deficit. As such, the concept of hopamine-as a reflection of the unique personal characteristics of each person with Parkinson's disease-really supplements that of dopamine-as a reflection of each person's unique physical characteristics. Whereas a prescription of dopamine replacement medication necessitates the diagnosed individual to lay his or her fate in the hands of medical professionals, adding a personalized dose of hopamine to the therapeutic mix empowers persons to self-manage daily life with Parkinson's disease. In this viewpoint, we argue that hopamine is a prerequisite for personalized medicine and offer several practical recommendations for how medical professionals can introduce the concept of hopamine in daily clinical practice.
Identifiants
pubmed: 36806516
pii: JPD230012
doi: 10.3233/JPD-230012
pmc: PMC10041418
doi:
Substances chimiques
Dopamine
VTD58H1Z2X
Dopamine Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
271-277Références
Death Stud. 2021;45(3):238-247
pubmed: 31192774
Disabil Rehabil. 2022 Nov;44(23):6949-6968
pubmed: 34592863
Am J Lifestyle Med. 2020 Mar 3;15(1):6-13
pubmed: 33456415
Parkinsonism Relat Disord. 2020 Jan;70:7-12
pubmed: 31785444
Health Informatics J. 2019 Mar;25(1):91-105
pubmed: 28434277
Mov Disord Clin Pract. 2016 May-Jun;3(3):250-256
pubmed: 27331078
BMC Med Inform Decis Mak. 2019 Aug 30;19(1):175
pubmed: 31470832
Patient Educ Couns. 2020 Sep;103(9):1709-1723
pubmed: 32299642
Cult Med Psychiatry. 2016 Mar;40(1):35-58
pubmed: 26194780
NPJ Parkinsons Dis. 2021 Jan 18;7(1):7
pubmed: 33462213
Behav Sci (Basel). 2019 Oct 10;9(10):
pubmed: 31658668
Med Humanit. 2017 Mar;43(1):35-40
pubmed: 27821537
BMC Neurol. 2021 Jan 22;21(1):34
pubmed: 33482753
Nat Rev Clin Oncol. 2011 May 31;8(7):444
pubmed: 21629214
Health (London). 2018 Sep;22(5):483-499
pubmed: 28637363
Lancet. 2021 Jun 12;397(10291):2284-2303
pubmed: 33848468
J Neurol. 2018 May;265(5):1151-1157
pubmed: 29546451
Lancet Oncol. 2020 Sep;21(9):e452-e459
pubmed: 32888474
Mov Disord. 2021 Jan;36(1):64-70
pubmed: 33094858